Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
Obstructive sleep apnea and obesity feed each other. Excess weight narrows the airway, poor sleep disrupts the hormones controlling appetite, and disrupted appetite drives further weight gain.
Breaking that cycle at the weight end has now been tested properly, and the results were substantial.
What obstructive sleep apnea is
During sleep, the muscles holding your upper airway open relax. In obstructive sleep apnea, the airway narrows or closes entirely, and breathing stops repeatedly through the night.
Each pause ends with a partial waking that you do not remember. Oxygen levels drop and recover repeatedly.
Severity is measured by the apnea-hypopnea index, the number of breathing interruptions per hour. Fifteen or more per hour is moderate to severe.
The consequences are considerable: daytime sleepiness, impaired concentration, raised blood pressure, increased cardiovascular risk, and higher accident risk while driving.
Why weight matters so much
Fat around the neck and throat narrows the airway physically, and the walls collapse more readily during sleep.
Fat in the abdomen reduces lung volume, which reduces the traction that helps keep the upper airway open.
Fat at the base of the tongue narrows the space further.
This is mechanical rather than metabolic, which is why weight change produces relatively fast improvement.
What the trial found
SURMOUNT-OSA, published in the New England Journal of Medicine in 2024, was a randomised placebo-controlled phase 3 trial running 52 weeks. It enrolled participants with moderate-to-severe obstructive sleep apnea, meaning an apnea-hypopnea index of 15 or more events per hour, and obesity with a BMI of 30 or above.
Participants received tirzepatide at 10 mg or 15 mg, or placebo, across two randomised trials.
Tirzepatide reduced:
- The apnea-hypopnea index
- Body weight
- Hypoxic burden, meaning the cumulative oxygen deprivation across the night
- hsCRP concentration, a marker of inflammation
- Systolic blood pressure
It also improved sleep-related patient-reported outcomes.
The breadth matters. Reducing apnea counts alone would be useful. Reducing oxygen deprivation, inflammation and blood pressure simultaneously addresses the routes by which sleep apnea causes cardiovascular harm.
The vicious cycle
Understanding this explains why sleep apnea is so difficult to escape through willpower.
Poor sleep raises ghrelin, the hunger hormone, and lowers leptin, which signals fullness. Short or fragmented sleep reliably increases appetite the following day.
Fatigue reduces activity. Someone waking exhausted is not going for a walk after dinner.
Fatigue drives carbohydrate craving, since the body seeks quick energy.
So sleep apnea makes weight loss harder, and excess weight makes sleep apnea worse. Each reinforces the other.
That also means improvement compounds in the right direction. Better sleep improves appetite regulation, which supports weight loss, which further improves the apnea.
What this does not replace
Worth stating clearly.
CPAP remains the primary treatment for moderate-to-severe obstructive sleep apnea. It works immediately and reliably by holding the airway open with air pressure.
Weight loss reduces severity over months. CPAP works tonight.
Anyone diagnosed with moderate-to-severe sleep apnea should not stop CPAP because they have started losing weight. Reassessment happens after meaningful weight change, with a repeat sleep study, and any change to CPAP use is a decision for the treating clinician.
The realistic framing is that weight loss can reduce severity, sometimes substantially, and in some cases enough to change treatment requirements. That is established by testing, not by assumption.
Recognising undiagnosed sleep apnea
A large share of cases are never diagnosed, particularly in Pakistan where sleep studies are less accessible.
Signs worth taking seriously:
- Loud snoring, particularly with pauses others notice
- Waking gasping or choking
- Daytime sleepiness despite adequate time in bed
- Morning headaches
- Waking unrefreshed
- Difficulty concentrating
- Irritability
- Needing to urinate several times at night
- Falling asleep watching television or, more seriously, while driving
If a partner reports that you stop breathing during sleep, that warrants assessment. Speak with a specialist about it rather than accepting it as normal snoring.
Falling asleep while driving is a medical emergency in practical terms and needs urgent attention.
The Pakistani context
Sleep apnea is substantially underdiagnosed here. Sleep studies are limited to larger cities and are expensive, CPAP machines are costly, and loud snoring is widely regarded as normal rather than a symptom.
South Asian populations also develop metabolic complications at lower BMI thresholds, and craniofacial structure influences airway dimensions independently of weight.
The practical consequence is that many people carry untreated sleep apnea, attribute the fatigue to work or age, and struggle with weight loss without knowing why appetite feels uncontrollable.
If that describes you, getting assessed is worth more than another diet attempt.
Where appetite support fits
If disrupted sleep is driving appetite through ghrelin and leptin, then addressing appetite directly interrupts the cycle at a different point.
Physician-guided appetite support works on the GLP-1 pathway as a physician-reviewed sublingual supplement with medical review before dispatch. METASLIM™ is not tirzepatide, and SURMOUNT-OSA describes tirzepatide rather than this product. Nobody should suggest the trial results transfer.
What does transfer is the mechanism. Weight reduction reduces apnea severity because the cause is mechanical, and that holds regardless of how the weight is lost.
Anyone with diagnosed sleep apnea should be raising it at any medical review, since it changes both the risk picture and the potential benefit.
Our guide to GLP-1 benefits beyond weight loss covers the wider evidence, and GLP-1 and heart health covers the cardiovascular overlap.
The summary
SURMOUNT-OSA, a 52-week phase 3 trial in people with moderate-to-severe sleep apnea and obesity, found tirzepatide reduced the apnea-hypopnea index, body weight, hypoxic burden, inflammation and systolic blood pressure.
Weight affects sleep apnea mechanically, through fat around the neck, at the tongue base and in the abdomen reducing lung volume.
Poor sleep raises ghrelin and lowers leptin, so untreated apnea makes weight loss harder. The cycle runs both ways.
CPAP remains the primary treatment and should not be stopped because weight loss has started. Reassessment requires a repeat sleep study.
Sleep apnea is substantially underdiagnosed in Pakistan, and loud snoring with pauses warrants assessment rather than acceptance.
See if you qualify for the program and raise any sleep symptoms at the review.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.